In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure

Diagnostic Microbiology and Infectious Disease

Volumn 55, Issue 1, 2006, Pages 81-83

  Yahav, Jacob ^a,b   Shmuely, Haim ^a,b   Niv, Yaron ^a,b   Bechor, Jacklin ^a,b   Samra, Zmira ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Helicobacter pylori; In vitro susceptibility, treatment; Levofloxacin

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; EVALUATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROBIAL SENSITIVITY TEST; PRIORITY JOURNAL; STOMACH BIOPSY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; TREATMENT FAILURE;

EID: 33646469364     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.12.003     Document Type: Article

References (18)

1. Branca G., Spanu T., Cammarota G., Schito A.M., Gasbarrini A., Gasbarrini G.B., and Fadda G. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int. J. Antimicrob. Agents 24 (2004) 433-438
2. Buckley M.J., Xia H.X., Hyde D.M., Keane C.T., and O'Morain C.A. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Diagn. Dis. Sci. 42 (1997) 2111-2115
3. Cabrita J., Oleastro M., Matos R., Manhente A., Cabral J., Barros R., Lopes A.I., Ramalho P., Neves B.C., and Guerreiro A.S. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46 (2000) 1029-1031
4. Cammarota G., Cianci R., Cannizzaro O., Cuoco L., Pirozzi G., Gasbarrini A., Armuzzi A., Zocco M.A., Santarelli L., Arancio F., and Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14 (2000) 1339-1343
5. Central Cancer Registry. Annual report (1995), Ministry of Health, Jerusalem, Israel
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement M100-S15 (2005), Clinical and Laboratory Standards Institute, Wayne, PA
7. Davis R., and Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47 (1994) 677-700
8. Huang J., and Hunt R.H. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment. Pharmacol. Ther. 13 (1999) 719-729
9. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother. 48 (2001) 77-80
10. Kim J.J., Kim J.G., and Kwon D.H. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 8 (2003) 202-206
11. Mégraud F., and Lamouliatte H. The treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. 17 (2003) 1333-1343
12. Parsonnet J. Helicobacter pylori: The size of the problem. Gut 1 Suppl. I (1998) S6-S9
13. Realdi G., Dore M.P., Piana A., Atzei A., Carta M., Cugia L., Manca A., Are B.M., Massarelli G., Mura I., Maida A., and Graham D.Y. Pretreatment antibiotic resistance in Helicobacter pylori infection: Results of three randomized studies. Helicobacter 4 (1999) 106-112
14. Samra Z., Shmuely H., Niv Y., Dinari G., Passaro D.J., Geler A., Gal E., Fishman M., Bachor J., and Yahav J. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J. Antimicrob. Chemother. 49 (2002) 1023-1026
15. Tankovic C., Lascols Q., Sculo J., Petit C., and Soussy C.J. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47 (2003) 3942-3944
16. Walsh J.H., and Peterson W.L. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 12 (1995) 984-991
17. Wang G., Wilson T.J., Jiang Q., and Taylor D.E. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 45 (2001) 727-733
18. Zullo A., Hassan C., De Francesco V., Lorenzetti R., Marignani M., Angeletti S., Ierardi E., and Morini S. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver Dis. 35 (2003) 232-236